Loading organizations...
§ Private Profile · San Francisco, CA, USA
A clinical-stage biopharmaceutical company developing non-opioid pain therapeutics for post-surgical pain management.
Based in San Francisco, California, Concentric Analgesics is a clinical-stage biopharmaceutical company that develops non-opioid pain therapeutics using novel TRPV1-agonist prodrugs. The organization currently operates with a team of 11 to 50 employees and has secured between $100 million and $500 million in venture capital and development financing. Its lead product, vocacapsaicin, is designed to provide long-lasting pain relief through a single local injection for patients treated in hospitals and surgical centers. The drug demonstrated efficacy over 96 hours in Phase 2 clinical trials and subsequently received Breakthrough Therapy designation from the Food and Drug Administration for post-surgical pain management. The enterprise is guided by industry veterans, including Thomas B. King, who joined the board of directors to help advance the clinical pipeline toward Phase 3 studies. Concentric Analgesics was officially founded in 2014.
Concentric Analgesics has raised $96.0M across 2 funding rounds.
Concentric Analgesics has raised $96.0M in total across 2 funding rounds.
Concentric Analgesics has raised $96.0M in total across 2 funding rounds.
Concentric Analgesics's investors include Jonathan R. Lynch, Larry Feinberg, Cowen Healthcare Investments, Kern Capital, Venrock.
Concentric Analgesics has raised $96.0M across 2 funding rounds. Most recently, it raised $20.0M Other Equity in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 26, 2022 | $20M Venture Round | Jonathan R. Lynch | — | Announced |
| May 21, 2019 | $76M Series B | Larry Feinberg | Cowen Healthcare Investments, Kern Capital, Venrock | Announced |